Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.54 |
| ▸ | NAAA | Q02083 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CASP2 | P42575 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | MLYCD | O95822 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20550286 | 0.85 | — | — | |
| SCHEMBL31467551 | 0.78 | EPHX1 (0.64) | EPHX1NAAAL3MBTL1HTTCASP2 | |
| SCHEMBL9979205 | 0.75 | SMN1; SMN2 (0.70) | EPHX1NAAAL3MBTL1TSHRHTT | |
| SCHEMBL17580836 | 0.75 | NAAA (0.54) | EPHX1NAAAL3MBTL1TSHRHTT | |
| SCHEMBL20550568 | 0.75 | — | — | |
| SCHEMBL11759620 | 0.74 | NAAA (0.49) | EPHX1NAAAL3MBTL1HPGD | |
| SCHEMBL1978767 | 0.73 | NAAA (0.71) | EPHX1NAAAL3MBTL1GPR84MLYCD | |
| SCHEMBL9265536 | 0.73 | L3MBTL1 (0.86) | NAAAL3MBTL1MLYCDALDH1A1SMN1; SMN2 | |
| SCHEMBL9978782 | 0.73 | NAAA (0.71) | EPHX1NAAAL3MBTL1GPR84MLYCD | |
| SCHEMBL9979011 | 0.73 | NAAA (0.71) | EPHX1NAAAL3MBTL1GPR84MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408300-B1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2016-05-11 | — | — | EP | disclosed |
| US-8232294-B2 | Amino ester derivatives, sailts thereof and methods of use | Xi, Ning (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2408300-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | Sunshine Lake Pharma Co., Ltd (CN) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010111063-A1 | AMINO ESTER DERIVATIVES, SALTS THEREOF AND METHODS OF USE | XI NING (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100239576-A1 | AMINO ESTER DERIVATIVES, SAILTS THEREOF AND METHODS OF USE | SRC, BCAT1, BCAT2 | EPHX1 1491/4885NAAA 2407/4885L3MBTL1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.